FDA Approves Liraglutide (Saxenda) for Weight Loss
The U.S. Food and Drug Administration has approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. See this week’s Item 11. "The approval of Saxenda adds a unique tool to the armamentarium of obesity medicine," said Louis J. Aronne, MD, FACP, Sanford I. Weill Professor of Metabolic Research and director of the Comprehensive Weight Control Center at Weill-Cornell Medical College in New York. "FDA approval of four new drugs in two years signals the beginning of a new era in which health care providers treat obesity, rather than the many comorbidities [that] result." Watch for our exclusive interview with Dr. Aronne in the coming weeks!
New guidelines from the American Diabetes Association recommend greater statin use. More to come in next week’s newsletter.